Vice President, Product Development
Art has more than 20 years of biomaterials, medical device and biotech experience in both public and private companies, with a strong record of developing technologies from bench top through commercialization. Prior to joining Ocular Therapeutix in 2011, Mr. Driscoll was Vice President of BioSurgery R&D for Covidien’s Surgical Solutions business and previously held senior management positions at Confluent Surgical and Boston Scientific.
Mr. Driscoll has a B.S degree in industrial technology and was a candidate for an M.S. degree in plastics engineering from the University of Lowell.